Can a coated catheter stop deadly ICU infections?

NCT ID NCT05959018

Completed Prevention Sponsor: University of Malaya Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using a catheter coated with antimicrobial medicine could prevent serious bloodstream infections in intensive care patients. Researchers compared the coated catheter to a standard one in 110 adults in a Malaysian hospital ICU. They looked at infection rates, length of hospital stay, and costs to see if the special catheter is worth the extra expense.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Antimicrobial-impregnated central venous catheter (Arrowg+ard Blue Plus®)
What this could lead to: If effective, this could show that antimicrobial-coated catheters reduce dangerous bloodstream infections and save healthcare costs in ICUs.
What could go wrong: This is a small, single-center study (110 participants) that is already completed. Results may not apply to other hospitals or countries, and the catheters are more expensive, so cost-effectiveness is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLABSI - CENTRAL LINE ASSOCIATED BLOODSTREAM INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLABSI - CENTRAL LINE ASSOCIATED BLOODSTREAM INFECTION

Contacts and locations

Locations

Universiti of Malaya Medical Centre

Kuala Lumpur, Kuala Lumpur, 59100, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.